文献速递男科与性医学前列腺癌

睾丸癌幸存者中勃起功能障碍与睾酮缺乏的发病率

Incidence of Erectile Dysfunction and Testosterone Deficiency in Testicular Cancer Survivors.
PubMed 文献 · J Urol · 2024-09-30

这项回顾性队列研究纳入1990至2021年美国退伍军人中1754例睾丸癌患者,与7117例年龄和种族匹配的非癌症对照比较。睾丸癌患者发生勃起功能障碍(HR 2.97,95%CI 2.68-3.28,P<.001)和睾酮缺乏(HR 6.71,95%CI 5.78-7.81,P<.001)的风险显著高于对照。在睾丸癌组内,是否接受化疗与勃起功能障碍和睾酮缺乏的发病率无显著差异(P=.9和P=.066)。

要点

  • 睾丸癌幸存者发生勃起功能障碍的风险约为非癌症对照的2.97倍(HR 2.97,95%CI 2.68-3.28,P<.001)。
  • 睾丸癌幸存者发生睾酮缺乏的风险约为非癌症对照的6.71倍(HR 6.71,95%CI 5.78-7.81,P<.001)。
  • 在睾丸癌组内,接受化疗与未接受化疗者勃起功能障碍和睾酮缺乏的发病率无显著差异(P=.9和P=.066)。

核心结论

  • 男性健康疾病在睾丸癌幸存者中常见,治疗医生应识别这些疾病并将性健康评估纳入生存者照护。

研究设计与样本

  • 回顾性队列研究,纳入1990至2021年美国退伍军人中诊断为睾丸癌的1754例患者,与7117例年龄和种族匹配的非癌症对照比较,平均诊断年龄42岁。

主要发现

  • 睾丸癌患者发生勃起功能障碍的风险显著高于对照(HR 2.97,95%CI 2.68-3.28,P<.001)。
  • 睾丸癌患者发生睾酮缺乏的风险显著高于对照(HR 6.71,95%CI 5.78-7.81,P<.001)。
  • 在睾丸癌组内,按是否接受化疗分层,勃起功能障碍和睾酮缺乏的发病率无显著差异(P=.9和P=.066)。

关键数值与推荐

  • 勃起功能障碍和睾酮缺乏定义为存在诊断代码或至少6个月的针对这些疾病的药物治疗处方,或两者兼有。

临床怎么用

  • 原文结论指出治疗医生应识别这些疾病并将性健康评估纳入生存者照护。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this project was to characterize the incidence of men's health disorders, specifically focusing on the incidence of erectile dysfunction (ED) and testosterone deficiency (TD) in a large, nationwide study of testicular cancer (TC) survivors treated in a centralized health care system. MATERIALS AND METHODS: We conducted a retrospective cohort study of US veterans diagnosed with TC from 1990 to 2021. These veterans were compared with an age-matched and race-matched control group of US veterans without a diagnosis of TC. ED and TD were defined by the presence of diagnosis codes or at least a 6-month prescription for medications treating these conditions or both. Time was measured from the date of TC diagnosis (for patients with TC and matched TC patient date for the corresponding noncancer controls). Impact of chemotherapy among TC survivors on ED and TD was evaluated using multivariable Cox regression models. RESULTS: The cohort included 1754 patients with TC compared with 7117 noncancer controls, with a mean age at diagnosis of 42 years. Patients with TC were significantly more likely than controls to experience ED (hazard ratio, 2.97; 95% CI, 2.68-3.28; P < .001) and TD (hazard ratio, 6.71; 95% CI, 5.78-7.81; P < .001). However, within the TC group, there was no significant difference in the incidence of ED and TD when stratified by receipt of chemotherapy (P = .9 and P = .066, respectively). CONCLUSIONS: Men's health disorders arise commonly in the lives of TC survivors. It is important for treating physicians to identify these and conduct sexual health assessments as part of survivorship care.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Pandit K, Riviere P, Morgan K, et al. Incidence of Erectile Dysfunction and Testosterone Deficiency in Testicular Cancer Survivors. J Urol. 2024. PMID: 39348687. doi:10.1097/JU.0000000000004259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。